Current Challenges in Health Economics
Transcript of Current Challenges in Health Economics
![Page 1: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/1.jpg)
Current Challenges in
Health Economics
Prof. Dr. Weerachai Kosuwon BSc., MSc.,MD.,FIMS
Director of Special Orthopedic skills training Center Khon Kaen University,
Director of Research Center for Orthopedic Biomechanics Khon Kaen University.
![Page 2: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/2.jpg)
Topics of my talk
• What is Health and Clinical Economics and its principles.
• Types of Health Economics
• Costs and types and Discounting
• Decision analysis
• Types of economic evaluation
• Sensitivity analysis
![Page 3: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/3.jpg)
What is Health?
• According to WHO constitution health is a state of complete physical, mental and social well being and not merely the absence of disease or infirmity
• “Health in health economic evaluation is health status according to some measures of resources available input for health and health-status outcomes.
• Economics deals with use of scarce resources to satisfy human wants and needs how best to use the resources available.
![Page 4: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/4.jpg)
Principal of Economic evaluations
Scarcity
Needs
Wants
Opportunity cost
Decision Analysis
![Page 5: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/5.jpg)
Health and Economics
• Health
• Human behavior
• Science
• Hospital, clinic, nursing-home, Home
health care
• Patients- Relatives and Health Providers
• Economics
• Human behavior
• Science
• Market
• Buyer and Seller
![Page 6: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/6.jpg)
Health care market
• กลมผใหบรการมไมมากกลม
• บรการทดแทนกนไมได
• ผใหบรการเปนผก าหนดบรการและราคา
• ผซอไมทราบคณภาพและชนดของบรการ
• แทรกแซงโดยรฐ (Extensive government interventions)
• Intractable uncertainty in several dimension of both input and output data
Supplier induces demand
![Page 7: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/7.jpg)
Types of Economics
• Microeconomics : unit cost, program evaluation
• Macroeconomics: Demand and Supply
• Trial-Based (RCT)Economic evaluation
• Modeling-Based Economic evaluation
![Page 8: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/8.jpg)
Costs
•Medical care cost
•Non-medical care cost
•Cost of productivity loss
•Cost of concerning (intangible cost)
![Page 9: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/9.jpg)
Types of cost
1. Direct cost 2. Indirect cost(Productivity loss)
3. Intangible cost
Medical Non-Medical
•Hospital stay
•Drug
•X-ray
•Surgery
•Lab.
•Traveling
•Food
•Baby sister•Hotel
![Page 10: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/10.jpg)
• Patient
• Provider
• Payer
• Society
Point of Views
S
patient
Provider
Payersociety society
![Page 11: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/11.jpg)
How to do cost analysis
1. Identify
2. Measure
3. Value
![Page 12: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/12.jpg)
![Page 13: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/13.jpg)
Cost analysis
• Cost is not a charge :
Item cost charge
CBC 102 68
Private ward (19) 1358 980
Appendectomy 5890 1500
![Page 14: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/14.jpg)
Nursing care cost
Identify Measure value
Nursing care •Working time (min)
•Workload
(NDNQI and ANA
I. ICU
II. OperatingIII. AE
Salary
Baht/minute
NDNQI : National Database of Nursing Quality IndicatorANA: American Nurses Association
![Page 15: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/15.jpg)
![Page 16: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/16.jpg)
Discounting in Economic Evaluations
Health care interventions incur costs and outcomes over a number of years.
Discounting seeks to take into account the impact of time on how those costs
and outcomes are valued.
“In general, individuals prefer to experience a good health status or consume a product now relative to doing so in the future.”
![Page 17: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/17.jpg)
![Page 18: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/18.jpg)
• Standard practice (Evan& Hurley 1995 discount rate 5%/yr.
• US Public Health (Gold et al. 1996) discount rate 3%/QALY gain
• World Bank (Jamison et al. 1993 discount rate 3%
![Page 19: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/19.jpg)
Principal of Economic evaluations
•Cost, Consequences, and their times.
•Two or more alternatives
•Decision and Sensitivity analyses
•Point of views
![Page 20: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/20.jpg)
Evaluation of Health Care
Are both costs & consequences examined?
Are
tw
o o
r m
ore
op
tio
ns
com
par
ed?
No Yes
No
Yes
Partial evaluation Partial evaluation
Partial evaluation Full economic
evaluation
![Page 21: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/21.jpg)
Economic evaluation
Input 1 Output 1
Input 2 Output 2
Economic efficiency = Output > input
![Page 22: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/22.jpg)
InputsCost
InterventionAlternatives
OutcomesConsequences
Identify
Measure
Value
Monetary U
Identify
Measure
Value
Monetary UClinical U Utility U
Economic Evaluations
![Page 23: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/23.jpg)
Input
+(Cost)
Output
+(Effect)
0
Input
-(Cost)
Output
-(Effect)
√
X ?Decision making
?
Decision making
![Page 24: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/24.jpg)
Decision analysis
• A systematic quantitative approach for assessing the relative value of one or more different decision options.
![Page 25: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/25.jpg)
ขนตอนการเขยน decision tree
• ก าหนดชนดของการรกษา หรอ ทดสอบ
• เขยนเสนกงกานของ ผลลพธทนาจะเกดขนในแตละการรกษาหรอทดสอบโดยเขยนเรยงล าดบการเกดกอนหลง
• ก าหนด ผลลพธสดทายไวสวนสดทายของแตละกง
• ก าหนดและเขยนคาความนาจะเปนของผลลพธแตละอน คาโอกาสของแตละกงตองรวมกนได 100 หรอ 1
เสมอ
• ค านวณคาเฉลยของความนาจะเปนของแตละกงทางเลอกการรกษาหรอทดสอบ
![Page 26: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/26.jpg)
สญญาลกษณตางๆทใชเขยน decision tree
• choice node
• chance node
• balloon
• final outcome
![Page 27: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/27.jpg)
Fall
Not fall
Not fall
Fall
fetal
Not fetal
fetal
Not fetal
fetal
Not fetal
fetal
Not fetal
Decision Tree
20%
50%
50%
50%
10%
1.Cost of preventive program
2.Cost of treatments due to fall
![Page 28: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/28.jpg)
![Page 29: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/29.jpg)
Economics Evaluations
•Cost-minimization analysis
•Cost-Effectiveness analysis
•Cost-Benefit analysis
•Cost-Utility analysis
![Page 30: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/30.jpg)
![Page 31: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/31.jpg)
Input 1 Output 1
Input 2 Output 2
Output 1 = Output 2
X
XEquivalent studies
Non-inferiority trial
Systematic review
![Page 32: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/32.jpg)
![Page 33: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/33.jpg)
![Page 34: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/34.jpg)
Cost-effectiveness analysis
Incremental Cost-Effectiveness analysi
![Page 35: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/35.jpg)
Cost-effectiveness analysis
Input 1 Output 1
Input 2 Output 2
![Page 36: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/36.jpg)
Cost-effectiveness ratio
Input A (24,000 baht of
Duloxatine treatment Program in 100 cases)
Output A
(Number of patient
painless = 85 cases
Cost-effectiveness ratio in A = Cost A
Output A
= 12,000 baht
45 cases
= 266 baht/case
Cost-effectiveness ratio in Dulox = cost Dulox
Output Dulox
= 24,000 baht
85
= 282 baht/case
![Page 37: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/37.jpg)
![Page 38: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/38.jpg)
![Page 39: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/39.jpg)
![Page 40: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/40.jpg)
Incremental cost-effectiveness ratio(ICER)
An important principle in the calculation of ICER dictated by the
economic theory underlying health economics research, is that each
relevant strategy should be compared with the next best alternative,
based on the economic concept of “opportunity costs”
“ถาจะเลอกการรกษาทใหผลดกวาเดม 1 หนวยตองลงทนเพม(ลด)ขน(ลง) เทาใด”
ICER = Cost new – Cost reference
Effect of new – Effect of reference
![Page 41: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/41.jpg)
ICER = cost New pain killer – cost Reference pain killer
Number of painless patients in New – Number of painless in Reference
= 24,000 – 12,00085 - 45
= (12,000/40)
= (300/1)
= ลงทนเพมขน 300 บาท เพอเพมจ านวน ผป ทไมปวด 1 คน
CR of New= 24,000/85= 282/case
CR of Reference= 12000/45= 266/case
![Page 42: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/42.jpg)
Cost-Benefit analysis
![Page 43: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/43.jpg)
Cost-Benefit analysis
• เปนการวเคราะหเปรยบเทยบตนทนและผลได(consequence) โดยผลไดจะวดออกมาเปนรปตวเงน
Cost (input) Cost (output)
• สามารถเปรยบเทยบโครงการหรอการรกษาทวดผลไดทางคลนกทแตกตางกนได
โครงการปองกนการเกดขอเขาเสอม vs. โครงการปองกนการเกดความดนโลหตสง
ขอเสย การตคาเปนเงนของ output
![Page 44: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/44.jpg)
Net Benefit= (Benefit T- Cost T) –(Benefit C- Cost C)
= (Benefit T- Benefit C) –(Cost T- Cost C)
(2000 -1000) - (700 -500)
(2000 – 700) – (1000 -500)
= +800
Positive net benefit means the treatment group is more benefit than the control group 800 unit.
![Page 45: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/45.jpg)
![Page 46: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/46.jpg)
![Page 47: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/47.jpg)
![Page 48: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/48.jpg)
Cost-Utility analysis
![Page 49: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/49.jpg)
Utility
• Utility is the value or worth of a level of health as measured by preferences
of an individual or society.
• Cost Utility analysis is one form of cost-effectiveness analysis which allowa
the comparison of different health outcomes by measuring them all in term
of a single unit (Quality adjusted life years, QALYs and Disability adjusted
life years, DALY)
Maurice McGregor
![Page 50: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/50.jpg)
Cost-Utility analysis
• เปลยนการตคา output หรอ consequence เปน Utility unit หรอ quality of life score
• วธวด utility score
1. Visual analog scale
2. Time-trade off
3. Standard gamble
4.Other methods (AQoL, EuroQol, Health Utility Index)
![Page 51: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/51.jpg)
Utility score
Health state Utility score
Migraine relief with no recurrence 1
Migraine relief, recurrence within 24 hr. 0.9
No relief, and patient endures migraine episode 0.3
No relief, patient attends emergency room,
finds relief 0.1
No relief, patient attends emergency room,
find no relief and hospitalized -0.3
![Page 52: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/52.jpg)
Utility MeasurementEuroQo (EQ-5D)
1. Mobility
2. Self-care
3. Usual activity
4. Pain/discomfort
5. Anxiety/depression
Each attribute has three levels:
1. No problem
2. Some problem
3. Major problem
Recent revised (added two health status: unconscious and dead)
Dolan et al. 1996
![Page 53: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/53.jpg)
Quality-adjusted life-year (QALY)
0
1
Utility score
Time0 6 12
Duloxatine group
Control group
QALY
![Page 54: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/54.jpg)
![Page 55: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/55.jpg)
![Page 56: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/56.jpg)
Economic analyses
Types of analysis
Input Output
Cost-minimization
Cost-effectiveness
Cost-benefit
Cost-utility
Cost
Cost
Cost
Cost
Clinical outcome
Clinical outcome
Cost
Utility score/QALY
![Page 57: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/57.jpg)
Cost-minimization
-Society
-Patient
-Payer
-Provider
Intangible
Indirect
Direct
Cost
Point
ofView
Cost-UtilityCost-Benefit
Cost-Effectiveness
Three-dimension of Economic Analysis
![Page 58: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/58.jpg)
Ceiling Ratio
Cost T- Cost C ▲ Cost
ICEA =
Effect T – Effect C ▲Effect
Ceiling Ratio = 50,000 C$/ QALYs <100,000 C$*
=40,000 A$/QALYs <70,000 A$**
< Ceiling Ratio
*Laupacis A, Feeny D 1992; CMAJ 146(4).473-81**George, Harris , Mitchell 2000 Pharmaceutical Benefits Schedule
![Page 59: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/59.jpg)
US$ 50,000 per QALYOwens DK. Interpretation of cost-effectiveness analysis. J Gen Intern Med 1998
Paltiel AD, et al. Resource allocation and the funding of HIV prevention.
In Handbook of Economic Evaluation of HIV Prevention Programs. 1998
AU$ 42,000-76,000 per QALYGeorge B, et al. Pharmacoeconomics 2001; 19
Ceiling ratio
![Page 60: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/60.jpg)
Ceiling ratio
•2-3 times of per capita GDP per QALY World Bank. The 1993 World Development Report,
Investing in Health.
Oxford University Press, Washington DC
•3 times of per capita income* per QALYCommission on Macroeconomics and Health.
Investing in Health for Economic Development.
WHO, 2001.
•In 2015, GDP per capita for Thailand = 5,720 US)The World Bank1103-1109.
![Page 61: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/61.jpg)
Sensitivity analysis
• Method to evaluate the stability of the conclusions of an analysis to
assumptions made and uncertainty variables in model inputs affects the
model outputs
![Page 62: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/62.jpg)
Types of sensitivity analysis
• Deterministic sensitivity analysis
• Probabilistic sensitivity analysis
![Page 63: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/63.jpg)
Types of sensitivity analysis
• One way sensitivity analysis
• Two ways sensitivity analysis
• Tornado Diagrams
• N-ways or multi-ways sensitivity analysis
Methods for calculation
1.Simple method
2. Probability method (Monte Carlo)
![Page 64: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/64.jpg)
95% confidence interval of▲ CE ratio(Deterministic Sensitivity analysis)
▲ cost
▲ effect
▲CU
▲ CL
▲EL ▲EU
point estimate
▲Cost/effect
![Page 65: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/65.jpg)
Probabilistic
Sensitivity analysis
• Confidence interval of estimation of cost-effectiveness ratio or cost-utility ratio
-E +E
-C
+C
![Page 66: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/66.jpg)
Probabilistic Sensitivity analysis• Confidence interval of estimation of cost-effectiveness ratio or cost-utility
ratio
-E +E
-C
+C
Ceiling ratio line
![Page 67: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/67.jpg)
![Page 68: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/68.jpg)
Cost-Utility analysis plane (A) and Cost-Utility analysis acceptability curve (B)
![Page 69: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/69.jpg)
![Page 70: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/70.jpg)
![Page 71: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/71.jpg)
Celebrex vs Doloxetine
$36,291 per QALY
![Page 72: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/72.jpg)
![Page 73: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/73.jpg)
![Page 74: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/74.jpg)
![Page 75: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/75.jpg)
![Page 76: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/76.jpg)
Cost Duloxetine (51,450) – Cost Naproxen (50,117)
QALY of Duloxetine (12.2123) – QALY of Naproxen(12.1899)
= 1,333/0.0224= $59,473/QALY
![Page 77: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/77.jpg)
![Page 78: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/78.jpg)
![Page 79: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/79.jpg)
50,000 ICER
![Page 80: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/80.jpg)
1.The model estimated an ICER of $59,473 for duloxetine over naproxen.
2. ICER under $30,000 were estimated for duloxetine over non-NSAIDs (Opioids)
3. In the higher risk of NSAID-related AEs, the ICER over naproxen was $33,105 or lower.
Duloxetin appears to be a cost-effective post-first-line treatment for CLBP compared with
all but generic NSAIDs.
![Page 81: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/81.jpg)
Topics of my talk
• What is Health and Clinical Economics and its principles.
• Types of Health Economics
• Costs and types and Discounting
• Decision analysis
• Types of economic evaluation
• Sensitivity analysis
Cost-minimization
-Society
-Patient
-Payer
-Provider
Intangible
Indirect
Direct
Cost
Point
ofView
Cost-UtilityCost-Benefit
Cost-Effectiveness
![Page 82: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/82.jpg)
เศรษฐศาสตรสาธารณะสข(Health Economics)
ธรรมชาตยอมเปนไปไดหลายหลาก ขอมลแมมมากหาพอไม
ประเมนคาไดหลายอยางตางกนไป ทรพยากรทหาไดไมเคยพอ
ตดสนใจบางคราวยากล าบากยง กเนองจากความจรงท งสขอ
ตดสนใจเพอคนไขไมอาจรอ แตละขอควรวเคราะหใหเหมาะเอยฯ
![Page 83: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/83.jpg)
![Page 84: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/84.jpg)
![Page 85: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/85.jpg)
![Page 86: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/86.jpg)
![Page 87: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/87.jpg)
![Page 88: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/88.jpg)
![Page 89: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/89.jpg)
![Page 90: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/90.jpg)
![Page 91: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/91.jpg)
![Page 92: Current Challenges in Health Economics](https://reader030.fdocuments.us/reader030/viewer/2022012107/61dc3c2eaf7cdc492e4d0405/html5/thumbnails/92.jpg)